In addition, bevacizumab, which is a mouse-human IgG1 chimeric antibody against vascular endothelial growth factor (VEGF) and first approved for colorectal cancer, had some clinical trial in which R/M HNSCC patients were enrolled [13]. The gene discussed is VEGFA; the disease is colorectal cancer.